Analysts Set Pyxis Oncology, Inc. (NASDAQ:PYXS) PT at $10.00

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given an average rating of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.00.

A number of equities analysts have recently commented on PYXS shares. Stephens initiated coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. William Blair downgraded Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Royal Bank of Canada upped their price objective on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, November 21st.

Pyxis Oncology Price Performance

NASDAQ PYXS opened at $1.62 on Friday. The company has a market cap of $96.34 million, a P/E ratio of -1.57 and a beta of 1.00. Pyxis Oncology has a 1-year low of $1.51 and a 1-year high of $6.85. The stock has a 50-day moving average of $3.10 and a two-hundred day moving average of $3.37.

Insider Activity

In other Pyxis Oncology news, CFO Pamela Ann Connealy bought 88,850 shares of the stock in a transaction dated Tuesday, November 26th. The stock was bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the purchase, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. The trade was a 8.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PYXS. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology during the second quarter worth about $40,000. Intech Investment Management LLC acquired a new stake in shares of Pyxis Oncology during the 3rd quarter worth approximately $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter worth approximately $58,000. The Manufacturers Life Insurance Company acquired a new position in Pyxis Oncology during the 2nd quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC grew its stake in Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after buying an additional 5,484 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.